

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

ANNOUNCEMENT

PROPOSED ISSUANCE OF CORPORATE BONDS

The Company and all members of the Board warrant the truthfulness, accuracy and completeness of the contents of this announcement and accept responsibility severally and jointly for any false statement or misleading representation herein or material omission herefrom.

On 10 December 2021, the board (the “**Board**”) of directors (the “**Directors**”) of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”) considered and approved the resolution in relation to the proposed issuance (the “**Proposed Issuance**”) of corporate bonds (the “**Corporate Bonds**”) by the Company in the People’s Republic of China (the “**PRC**”), subject to approval of its shareholders by way of special resolution at an extraordinary general meeting of the Company (the “**EGM**”) and approval of relevant regulatory authorities. The principal terms of the Proposed Issuance are set out below:

1. ISSUE SIZE

The Company proposes to issue the Corporate Bonds with a total principal amount not exceeding RMB1,500,000,000 (including RMB1,500,000,000) in multiple tranches.

2. TARGET SUBSCRIBERS

The Corporate Bonds are proposed to be issued to professional investors.

3. TERM

The Corporate Bonds will have a term of maturity not exceeding five years (including five years).

4. GUARANTEE

The Proposed Issuance will be guaranteed by Shenzhen Gaoxin Investment and Financing Guarantee Co., Ltd.* (深圳市高新投融资擔保有限公司), an independent third party of the Company and a financial guarantee service provider.

5. USE OF PROCEEDS

The Company intends to apply the net proceeds to be raised from the Proposed Issuance (“**Proceeds**”) to repay the Company’s debts, adjust the debt structure and replenish the working capital of the Company. The resolution authorising the Board and its authorised individuals to determine the specific manner and proportion of the use of Proceeds in accordance with the actual needs of the Company shall be considered by way of special resolution at the EGM.

6. VALIDITY OF THE RESOLUTION(S)

The resolution(s) approving the Proposed Issuance will be valid for 24 months commencing from the date of passing of the respective resolution(s) at the meeting of the Board and the EGM respectively, whichever is later.

The resolution(s) approving the Proposed Issuance at the EGM can only be executed after being considered and approved by way of special resolution at such general meeting.

A circular containing, among other things, details of the Proposed Issuance together with a notice convening the EGM to approve, among other matters, the resolution(s) in respect of the Proposed Issuance, will be despatched to the shareholders of the Company in due course.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li
Chairman

Shenzhen, the PRC
10 December, 2021

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Bin; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.

* *for identification purposes only*